Medicover AB financials
Medicover AB
Country: SE Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
5493000E9BUOYMOW2K53 Financial statements
(EUR, as reported — unscaled; 109 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Cost of sales | €1.64B | €1.39B |
| Gross profit | €448.3M | €359.4M |
| Administrative expenses | €280.2M | €220.1M |
| Operating profit (EBIT) | €70.3M | €61.4M |
| Net finance income / (cost) | -€50.6M | -€45.9M |
| Profit before tax | €20.1M | €23.6M |
| Income tax expense | €5.5M | €5.2M |
| Profit for the year | €14.6M | €18.4M |
| — attributable to owners | €16.7M | €17.6M |
| — attributable to NCI | -€2.1M | €800.0K |
| Total comprehensive income | €26.4M | €48.2M |
| Cash flow statement | ||
| Net cash from operating activities | €261.9M | €205.0M |
| Net cash from investing activities | -€134.7M | -€119.8M |
| Net cash from financing activities | -€108.0M | -€73.7M |
| Dividends paid | €18.0M | €17.9M |
| Proceeds from borrowings | €884.8M | €461.9M |
| Repayments of borrowings | €755.0M | €397.3M |
| Lease liability payments | €74.2M | €65.5M |
| Net change in cash | €19.2M | €11.5M |
| Balance sheet | ||
| Total assets | €2.14B | — |
| Non-current assets | €1.69B | €1.56B |
| Property, plant & equipment | €492.1M | €464.1M |
| Right-of-use assets | €483.7M | €411.6M |
| Intangible assets & goodwill | €524.1M | €517.0M |
| Current assets | €446.7M | €381.3M |
| Inventories | €69.1M | €59.4M |
| Trade & other receivables | €294.8M | €257.5M |
| Cash & equivalents | €69.8M | €50.8M |
| Total equity | €489.3M | €528.3M |
| — attributable to owners | €464.8M | €496.5M |
| Non-controlling interests | €24.5M | €31.8M |
| Non-current liabilities | €1.08B | €912.4M |
| Long-term borrowings | €543.1M | €406.4M |
| Lease liabilities (non-current) | €437.5M | €368.2M |
| Current liabilities | €566.3M | €500.6M |
| Lease liabilities (current) | €79.6M | €70.6M |
| Trade & other payables | €249.4M | €204.6M |
| Deferred tax liabilities | €34.9M | €41.2M |
| Derived metrics | ||
| Free cash flow | €139.6M | €94.5M |
| Return on equity | 3.0% | 3.5% |
| Cash conversion ratio | 17.94× | 11.14× |
| Capex coverage | 2.14× | 1.86× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€8.2M | -€5.1M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€53.3M | -€29.1M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €214.6M | €182.4M |
| Adjustments For Finance Income Cost | -€54.0M | -€47.0M |
| Adjustments For Increase Decrease In Trade and Other Payables | €43.5M | €19.8M |
| Adjustments For Sharebased Payments | €12.2M | €9.4M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€1.7M | -€6.5M |
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | €200.0K | €7.6M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €100.0K | €14.0M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €279.9M | €219.4M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €18.1M | €19.6M |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €300.0K | €100.0K |
| Comprehensive Income Attributable To Noncontrolling Interests | -€1.2M | €500.0K |
| Comprehensive Income Attributable To Owners of Parent | €27.6M | €47.7M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €178.7M | €158.5M |
| Current Contract Liabilities For Performance Obligations Satisfied Over Time | €14.0M | €9.8M |
| Current Financial Assets At Fair Value Through Profit Or Loss Mandatorily Measured At Fair Value | €10.7M | €8.9M |
| Current Tax Liabilities Current | €15.7M | €13.3M |
| Deferred Tax Assets | €39.7M | €27.3M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €18.0M | €17.9M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €2.8M | €3.8M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €22.5M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.15 | — |
| Dividends Received From Associates Classified As Investing Activities | €300.0K | €100.0K |
| Dividends Recognised As Distributions To Owners Per Share | €0.12 | €0.12 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€200.0K | -€1.1M |
| Equity and Liabilities | €2.14B | — |
| Gains Losses On Cash Flow Hedges Before Tax | -€400.0K | -€1.0M |
| Gains Losses On Exchange Differences On Translation Before Tax | €12.0M | €31.0M |
| Income Tax Relating To Exchange Differences On Translation of Other Comprehensive Income | -€200.0K | €200.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €19.2M | €28.8M |
| Increase Decrease In Cash and Cash Equivalents | €19.2M | €11.5M |
| Increase Decrease Through Acquisition of Subsidiary | €200.0K | -€800.0K |
| Increase Decrease Through Change In Equity of Subsidiaries | -€200.0K | -€100.0K |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | -€59.2M | -€3.3M |
| Increase Decrease Through Exercise of Options | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €12.0M | €8.9M |
| Increase Decrease Through Transactions With Owners | -€65.4M | -€28.4M |
| Increase Decrease Through Transfers and Other Changes Equity | -€200.0K | -€15.2M |
| Insurance Contracts Issued That Are Liabilities | €28.5M | €25.1M |
| Intangible Assets Other Than Goodwill | €133.2M | €122.2M |
| Interest Expense | €58.8M | €51.4M |
| Interest Paid Classified As Financing Activities | €59.4M | €46.5M |
| Interest Received Classified As Investing Activities | €5.3M | €3.9M |
| Investments In Associates Accounted For Using Equity Method | €700.0K | €800.0K |
| Issue of Equity | — | €300.0K |
| Liabilities | €1.65B | — |
| Other Adjustments For Noncash Items | -€100.0K | -€7.7M |
| Other Comprehensive Income | €11.8M | €29.8M |
| Other Current Financial Assets | €2.3M | €4.7M |
| Other Current Financial Liabilities | €400.0K | €18.7M |
| Other Finance Income Cost | €3.4M | €1.1M |
| Other Gains Losses | €400.0K | €8.0M |
| Other Inflows Outflows of Cash Classified As Investing Activities | €23.3M | €19.4M |
| Other Noncurrent Financial Assets | €16.8M | €16.4M |
| Other Noncurrent Financial Liabilities | €64.7M | €94.4M |
| Other Noncurrent Nonfinancial Assets | €1.2M | €600.0K |
| Payments From Changes In Ownership Interests In Subsidiaries | €83.4M | €4.6M |
| Payments To Acquire Or Redeem Entitys Shares | €0 | €300.0K |
| Proceeds From Disposal of Noncurrent Assets Or Disposal Groups Classified As Held For Sale and Discontinued Operations | €2.2M | €1.4M |
| Proceeds From Issuing Shares | €0 | €300.0K |
| Provisions | €2.4M | €2.2M |
| Purchase of Financial Instruments Classified As Investing Activities | €25.6M | €21.0M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €122.3M | €110.5M |
| Purchase of Treasury Shares | — | €300.0K |
| Revenue From Interest | €4.8M | €4.4M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | €0 | €100.0K |
Methodology
Every line item above is a fact tagged in Medicover AB's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.